Integrated Whole-Genome Analysis of Hematologic Disorders Using High-Throughput Sequencing and Array Technologies
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Hematologic Diseases
- Sponsor
- Stanford University
- Enrollment
- 35
- Locations
- 1
- Primary Endpoint
- to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
We will use new technologies to look at the DNA, RNA, proteins, and metabolites in the disease-containing blood, bone marrow, or tissue and normal cells from the skin. Our goal is to analyze all of the genes in the diseased and normal skin sample. By comparing the results of the diseased sample and normal skin cells and the results of the two types of genetic information (DNA and RNA), we should be able to identify genetic changes that are important for the initiation, progression, or treatment response of that particular disorder.
Investigators
Jason D. Merker
Assistant Professor of Pathology
Stanford University
Eligibility Criteria
Inclusion Criteria
- •18 years of age or older
- •Patient meets the clinical and/or pathologic criteria for the hematologic disorder being examined.
- •Patient is willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
Exclusion Criteria
- •Less than 18 years of age
- •Patient is not willing to provide a skin biopsy and five 10 mL tubes of peripheral blood.
Outcomes
Primary Outcomes
to identify mutations, changes in DNA copy number, structural rearrangements, or altered coding and non-coding RNA expression
Time Frame: sample collection at time of routine visit